41 results about "Immunoglobulin A" patented technology

The invention relates to the technical field of molecular biological detection, in particular to an SNP molecular marker related to immune traits of yaks and application of the SNP molecular marker. According to the invention, the SNP molecular marker related to the immune traits of yaks is obtained through screening and is located at the 55577127th position on the 22 # chromosome of a yak reference genome LUBosgruv3.0 version, and a mutant basic group is G or A. The content of immune globulin A, immune globulin G and immune globulin M of a yak individual can be obtained by utilizing the SNP molecular marker, a new SNP molecular marker resource is provided for non-diagnostic yak immune character marker-assisted selection, and a basis is provided for high-immunity yak breeding.

Provided is an immunological measurement method for measuring a target substance in a sample, wherein an antigen-antibody reaction is performed at least once in the presence of an enzyme that specifically decomposes immunoglobulin A, abbreviated as IgA.

The present invention provides an immunologic stimulant which contains Lactobacillus helveticus, and wherein the Lactobacillus helveticus has three functions: the activation of dendritic cell-like cells, the induction of the production of immunoglobulin A (IgA), and the induction of the production of interleukin-12 (IL-12).

The present invention belongs to the technical field of molecular biological detection, and in particular to a molecular marker g8087186 for rapid identification of Tibetan sheep immunity and its application. The present invention obtains a SNP molecular marker g8087186 related to Tibetan sheep immune traits by screening, which is located at the 8087186th base on chromosome 3 of the sheep reference genome group Oar_v4.0 version, and the mutant base is G or C. The SNP molecular marker can be used to obtain the content of immunoglobulin A, immunoglobulin G, and immunoglobulin M of Tibetan sheep individuals, and provides a new SNP molecular marker resource for marker-assisted selection of Tibetan sheep immune traits for non-diagnostic purposes. Provide a basis for breeding Tibetan sheep with high immunity.

The inventions relates to Immunoglobulin A (IgA) or a pharmaceutical composition comprising IgA for use in the treatment of an infectious disease of or in an immune privileged organ, such as the eye, fetus, placenta, central nervous system (CNS) and / or testicles caused by a bacterial, fungal, viral or parasitic infection, in particular caused by bacteria of the human microbiome. IgA-coated pathogens can be addressed by FCAR+ and / or CD11c+ innate immune cells, for example by phagocytosis, or by activation of the complement system. The use of IgA or a pharmaceutical composition comprising IgA in immune privileged sites is advantageous because in contrast to IgG, IgA-coated pathogens do not trigger activation of C1q, a protein used for the controlled pruning of synapses. This prevents neuronal damage in said immune privileged organ(s), while at the same time allowing an antibody-mediated immune response in said organs.

The present invention belongs to the technical field of livestock molecular biology detection, and in particular, relates to the KCNJ6 gene as a molecular marker for yak immune traits and its application. The KCNJ6 gene is used as a molecular marker for yak immune traits, and the nucleotide sequence of the molecular marker is shown in SEQ ID NO: 1. The y at the 401st position of the sequence represents T or C, resulting in the T / C polymorphism of the yak KCNJ6 gene at this site. The present invention can determine the immunoglobulin A, immunoglobulin G, and immune content of individual yaks by detecting the base at the 163690745th nucleotide site on chromosome 1 of the yak. ​​The present invention provides a new SNP molecular marker resource for marker-assisted selection of yak immune traits for non-diagnostic purposes.

The present application provides an immunostimulant containing Lactobacillus helveticus, wherein the Lactobacillus helveticus has three functions: activation of dendritic cell-like cells, induction of immunoglobulin A (IgA) production, and induction of interleukin-12 (IL-12) production.

The present invention belongs to the field of molecular biological detection technology, and in particular, relates to a molecular marker-assisted breeding method for Tibetan sheep with strong disease resistance. The present invention obtains a molecular marker for assisting the breeding of Tibetan sheep with strong disease resistance through screening, and the molecular marker is located at the 164719075th base on chromosome 3 of the sheep reference genome Oar_v4.0 version, and the mutant base is T or C. The molecular marker can be used to obtain the content of immunoglobulin A, immunoglobulin G, and immunoglobulin M of Tibetan sheep individuals, and provides a new molecular marker resource for marker-assisted selection of Tibetan sheep immune traits for non-diagnostic purposes. Provide a basis for breeding Tibetan sheep with high immunity.

The invention relates to application of aesculetin in preparation of a preparation for improving the health condition of poultry animals. The improved poultry animal abnormal indexes caused by heat stress comprise body weight, feed intake, daily gain, thymus index, spleen index, bursa of Fabricius index, thymus volume, spleen volume, bursa of Fabricius volume, total protein, serum albumin, interleukin-10, immune globulin A, immune globulin G, immune globulin M, triglyceride, total cholesterol and glutamic-pyruvic transaminase. The vaccine is prepared from the following raw materials: alkaline phosphatase, glutamic oxalacetic transaminase, urea nitrogen, lactic dehydrogenase, creatinine, heat shock protein 70, interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, interleukin-gamma, MyD88, TLR4, RELA, CD3 and CD19.

An immunological assay method for measuring a target substance in a sample, wherein at least one antigen-antibody reaction is performed in the presence of an enzyme that specifically decomposes immunoglobulin A (IgA).

The present disclosure refers to Immunoglobulin A (IgA) for use in a method for treating or preventing dry eyes in a patient wherein said Immunoglobulin A (IgA) is obtained from plasma, blood plasma or plasma fractions, and wherein said Immunoglobulin A (IgA) is administered to said patient in an effective dosage. In particular, the disclosure pertains to the use in a treatment or prevention of dry eye disease and the respective complications like infections. Further, the disclosure refers to IgA obtained from plasma, blood plasma or plasma fractions and a pharmaceutical composition comprising such IgA.

The invention provides a monoclonal antibody of immunoglobulin A. The monoclonal antibody is a monoclonal antibody of specific immunoglobulin A secreted by a mouse anti-human immunoglobulin A monoclonal antibody hybridoma cell line 5F5A4F3 strain, can be used for quantitatively detecting the concentration of RBD-IgA generated by stimulation of a specific antigen, and also can be used for quantitatively detecting the concentration of the immunoglobulin A. The immunoglobulin A monoclonal antibody can be used for detecting the immunoglobulin A monoclonal antibody, can also be used for quantitatively detecting the concentration of total IgA generated by mucosal immunity, and is good in linearity, high in sensitivity, strong in specificity, suitable for evaluating the immune effect of vaccines, and also suitable for screening and monitoring the IgA antibody level in large-scale people.

The present invention relates to the field of molecular biology detection technologies, and particularly to SNP molecular markers related to the immune traits of yaks and their applications. The present invention screens out SNP molecular markers related to the immune traits of yaks, which are located at position 55577127 on chromosome 22 of the yak reference genome LU_Bosgru_v3.0 version, and the mutated base is G or A. The present invention can obtain the contents of immunoglobulin A, immunoglobulin G, and immunoglobulin M of yak individuals by using this SNP molecular marker, providing a new SNP molecular marker resource for marker-assisted selection of yak immune traits for non-diagnostic purposes and providing a basis for breeding yaks with high immunity.

The present invention provides a recombinant fusion protein based on AK183 protease and its application in treating IgA nephropathy and other related diseases mediated by IgA complex deposition, wherein the recombinant fusion protein structure comprises a human commensal bacteria protease AK183 active region and a human immunoglobulin fragment; the human immunoglobulin fragment is located at the N-terminus of the protease AK183 active region. The present invention also provides a method for preparing the recombinant fusion protein. The recombinant fusion protein of the present invention has the comprehensive advantages of prolonged plasma half-life, effective clearance of circulating and renal IgA complexes, and greatly reducing the immunogenic side effects of the protease on the human body, by recombinantly fusing the natural AK183 protease with the human immunoglobulin fragment, and is suitable for specific treatment of IgA nephropathy and other related diseases mediated by IgA complex deposition.

A composition of matter including an IgG4-binding moiety, a cellular receptor-binding moiety which binds to hepatocytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells in a patient or subject, and optionally, a linker moiety connecting the IgG4-binding moiety and the cellular receptor-binding moiety, wherein the composition of matter is useful for removing IgG4 from a subject or patient.

A composition of matter including a deglycosylated IgA-binding moiety, a cellular receptor-binding moiety that binds to hepatocytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells in a patient or subject, and optionally, a linker moiety connecting deglycosylated IgA-binding moiety and the cellular receptor-binding moiety, wherein the composition of matter is useful for removing galactose-deficient IgA1 in a patient or subject.

A molecular marker associated with immune parameters in yaks and use thereof in breeding are provided. A single nucleotide polymorphism (SNP) molecular marker associated with immune traits in yaks is identified through screening. The SNP molecular marker is located at position 26593056 on chromosome 3 of the yak reference genome version LU_Bosgru_v3.0, and a nucleotide at the position is G or A. The SNP molecular marker is utilized to quantify levels of immunoglobulin A, immunoglobulin G, and immunoglobulin M in a yak individual, providing a novel SNP molecular marker resource for non-diagnostic, marker-assisted selection of immune traits in yaks, thereby providing a basis for breeding yaks with enhanced immune competence.

The present invention discloses a composite formulation for fasting-induced physiological remodeling in laying hens and its application, belonging to the technical field of fasting-induced physiological remodeling. The composite formulation and method provided by the present invention can significantly increase the ileal villus height, the expression levels of intestinal barrier-related genes and intestinal proliferation-related genes of laying hens, significantly reduce the expression levels of intestinal pro-inflammatory-related genes, alleviate intestinal stress damage and inflammation, and thus significantly improve the intestinal health of laying hens; can significantly increase the expression levels of immunoglobulin A, immunoglobulin G, and immunoglobulin M, and thus improve the immune performance of laying hens; with the improvement of intestinal health and immunity, fasting-induced physiological remodeling of laying hens is successfully achieved: the weight and egg production recovery ability of laying hens after fasting, and the yolk color depth on the 30th day after fasting are significantly better than those of the control group, providing technical support for the extended breeding of laying hens, saving costs and increasing efficiency.

To provide a treatment of AL amyloidosis by combination of a monoclonal antibody to an immunoglobulin light chain and a monoclonal antibody to a CD38 cell membrane molecule on antibody-producing cells or other immune cells.SOLUTION: Disclosed is a treatment of AL amyloidosis by combination of a monoclonal antibody against an immunoglobulin a light chain and aggregates thereof and a monoclonal antibody against a CD38 cell membrane molecule on antibody-producing or other immune cells. Typically, the effective dosage of these antibodies is effective to achieve an improvement in both hematologic and cardiac or other organ function. The dosage may be effective to achieve an improvement in both hematologic and organ function, for example, cardiac function.SELECTED DRAWING: None

A composition of matter including a deglycosylated IgA-binding moiety, a cellular receptor-binding moiety that binds to hepatocytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells in a patient or subject, and optionally, a linker moiety connecting deglycosylated IgA-binding moiety and the cellular receptor-binding moiety, wherein the composition of matter is useful for removing galactose-deficient IgA1 in a patient or subject.

Provided is a method of removal a pathogenic species from a system of a patient having Immunoglobulin A ("IgA") nephropathy by administering to the patient a degrader of galactose-deficient Immunoglobulin A ("Gd-IgA"), wherein the pathogenic species is a monomeric Gd-IgA, a dimeric Gd-IgA complex, a trimeric Gd-IgA complex, a tetrameric Gd-IgA complex, or a combination thereof.

The invention provides a method for removing IgA (Immunoglobulin A) and IgM (Immunoglobulin M) in human immunoglobulin for intravenous injection. The method comprises the following steps: S1) dissolving plasma component II + III precipitates to obtain a dissolved solution; s2) precipitating and centrifuging the dissolved solution by adopting n-caprylic acid or sodium caprylate to obtain supernate; s3) performing anion exchange column chromatography on the supernate to obtain first flow-through liquid and first washing liquid; s4) mixing the first flow-through liquid with the first washing liquid to obtain a column chromatography collection liquid; s5) performing strong anion membrane chromatography on the column chromatography collection liquid to obtain second flow-through liquid and second washing liquid; s6) mixing the second flow-through liquid and the second washing liquid to obtain a membrane chromatography collection liquid, and S7) sequentially performing first concentration, dialysis, first sterilization, incubation, ultrafiltration and second sterilization on the membrane chromatography collection liquid to obtain the human immunoglobulin for intravenous injection without IgA and IgM. According to the method disclosed by the invention, the IgA and IgM removal efficiency is remarkably improved through a multi-stage purification process.

A method of preventing or treating or controlling a respiratory disease in a bovine by delivering to a lung or trachea of the bovine a composition including a polyplex having one or more mRNA encoded with a molecule selected from lycosylphosphatidylinositol (GPI) complex, antibody immunoglobulin G (IgG), antibody immunoglobulin A (IgA), antibody immunoglobulin M (IgM), antimicrobial peptide Bactenecin 5 (Bac5), antimicrobial peptide Bactenecin 7 (Bac7), bovine myeloid antimicrobial peptide (BMAP-28), lipoxin inducing enzymes, resolvin inducing enzymes, cytokines, CRISPR associated protein 13 (Cas13) enzymes, nanoluciferase (NLuc) proteins, and gene activator, catalytically dead CRISPR-associated protein 9 fused to an activator selected from the group consisting of VP64-p65-Rta transactivation domain (dCas9-VPR), VP64, and VP64-p65-HSF1 on the N terminus and SS18 on the C-terminus, and a polymer prepared by polymerizing a diacrylate monomer; one or more linker monomers; and one or more branching monomers; and end-capping the polymer.

The present invention belongs to the field of molecular biological detection technology, and more particularly relates to a molecular marker associated with immune indicators in Tibetan sheep and its application in breeding. The present invention screens and identifies a single-nucleotide polymorphism (SNP) molecular marker associated with immune traits in Tibetan sheep. The SNP marker is located at base 12,065,580 on chromosome 1 of the sheep reference genome Oar_v4.0, with the mutated base being either C or T. This SNP molecular marker can be used to determine the levels of immunoglobulin A, immunoglobulin G, and immunoglobulin M in individual Tibetan sheep, providing a new SNP molecular marker resource for marker-assisted selection of immune traits in Tibetan sheep for non-diagnostic purposes. This provides a basis for breeding Tibetan sheep with high immunity.

The invention discloses a compound preparation for fasting-induced physiological remodeling of laying hens and application of the compound preparation, and belongs to the technical field of fasting-induced physiological remodeling. By adopting the compound preparation and the method provided by the invention, the intestinal villus height of laying hens and the expression quantity of intestinal barrier related genes and intestinal proliferation related genes can be remarkably improved, the expression quantity of intestinal proinflammatory related genes can be remarkably reduced, the stress injury and inflammation of intestinal tracts can be relieved, and the intestinal health degree of the laying hens can be remarkably improved; the expression quantity of immune globulin A, immune globulin G and immune globulin M can be obviously improved, so that the immune performance of laying hens is improved; with the improvement of intestinal health degree and immunity, fasting-induced physiological remodeling of the laying hens is successfully realized: the weight and laying rate recovery capability of the laying hens after fasting and the yolk color depth in the 30th day after fasting are remarkably superior to those of a control group, and a technical guarantee is provided for delayed raising, cost saving and efficiency improvement of the laying hens.

The present invention discloses a recombinant immunoglobulin A complex, its preparation method and uses. The recombinant poly-IgA protein is named rPolyIgA and is composed of a recombinant human IgA amino acid fragment, biotin and streptavidin. The amino acid sequence of the recombinant human IgA amino acid fragment is as shown in SEQ ID No.1. The preparation method of the recombinant poly-IgA protein includes obtaining the recombinant human IgA amino acid fragment; connecting biotin to obtain an intermediate product; and mixing with streptavidin and heating to obtain the recombinant poly-IgA protein. During the process of preparing the rPolyIgA, an expression plasmid and an expression cell are also included. The prepared rPolyIgA can be applied to calibration products for IgA immunoassay and the research and development of IgA immunological drugs.

The invention discloses a method for high-throughput synchronous analysis of complete O-glycopeptide and N-glycopeptide of immunoglobulin A, and belongs to the technical field of protein analysis. The method comprises the following steps: (1) separating IgA from a sample; (2) preparation and enrichment of IgA glycopeptide; and (3) detecting the IgA glycopeptide by mass spectrometry. According to the method, IgA is separated and purified through electrophoresis, IgA glycopeptides are enriched through a nano material, accurate molecular mass information (observed values) and information provided by a database are obtained through a high-resolution mass spectrum, corresponding possible glycopeptides are speculated, the theoretical molecular weight of the glycopeptides is calculated, and 93 kinds of glycopeptides including N-glycopeptides and O-glycopeptides are totally identified. According to the method, complete N glycopeptides and O glycopeptides of IgA in serum / plasma and other IgA-containing body fluid samples can be simultaneously determined, and information of glycoforms and glycosylation sites on the glycopeptides is reserved. The method has the advantages of strong operability, high sensitivity, good accuracy and good stability.

The invention provides an oral plant-probiotic heterologous multifunctional fusion exosome for targeted regulation and control of intestinal mucosa pIgR-IgA transport axis as well as a preparation method and application of the oral plant-probiotic heterologous multifunctional fusion exosome. The fusion exosome is constructed from a plant-derived exosome (such as a garlic exosome) and a probiotic-derived exosome (such as a bacteroides polymorpha exosome) through an ultrasonic membrane fusion technology. According to the invention, the fusion exosome is orally taken for the first time to specifically enhance the transfer of immune globulin A (IgA) mediated by a polyimmunoglobulin receptor (pIgR), so that the concentration of secreted IgA (SIgA) in an enteric cavity is improved, and the immune homeostasis of intestinal mucosa is fundamentally remodeled. In-vitro and in-vivo experiments prove that the core product GB-EV (garlic-bacteroides polymorpha fusion exosome) disclosed by the invention has excellent oral stability and colon targeting property, and can synergistically exert multiple effects of resisting oxidation, resisting inflammation, repairing intestinal barriers and reconstructing flora ecological balance; in an inflammatory bowel disease (IBD) prevention and treatment model, the exosome shows an excellent effect which is obviously superior to that of a single-source exosome and a control fusion exosome. The invention provides a brand new strategy for non-invasive targeted therapy of IBD.

Provided herein are glycoengineered polypeptides comprising: a first portion comprising one or more peptides that specifically bind to a target antibody (e.g., IgA1 or an immune complex comprising same, gd-IgA1 or an immune complex comprising same, or an anti-gd-IgA1 autoantibody or an immune complex comprising same); and a second portion comprising one or more glycans conjugated to the first portion at one or more glycosylation sites. Also provided herein are nucleic acid sequences encoding the provided glycoengineered polypeptides. Further provided herein are compositions comprising the glycoengineered polypeptides and / or nucleic acids encoding same, as well as methods of making and using them.

The present invention discloses a method for identifying and selecting the germplasm quality of musk deer suitable for plateau breeding, and belongs to the field of biotechnology and animal breeding technology. The method comprises the following steps: collecting fresh feces of musk deer; extracting fecal hormones and immunoglobulin A; determining the concentrations of fecal hormones and immunoglobulin A; dividing the three physiological and immune parameters into a high-content group, a medium-content group, and a low-content group, and calculating the proportion of each group; selecting musk deer individuals with low sensitivity, high energy metabolism, and high intestinal immunity; and selecting musk deer individuals suitable for plateau breeding. The present invention discloses a method for identifying and selecting the germplasm quality of musk deer suitable for plateau breeding. By adopting a non-invasive fresh feces sampling method to determine the three physiological and immune parameters in musk deer feces, the scientific identification and selection of the germplasm quality of musk deer suitable for plateau breeding is achieved.